About

Katherine Kovacs brings over 25 years of successful commercial experience in the life science industry. Specializing in insight-driven market research services, she leverages her background in strategic planning, public health, and project management. Her experience spans qualitative and quantitative research across diverse therapeutic areas, including biologics, vaccines, and generics.

As a consultant, Katherine collaborates with both large and small pharma companies, as well as market research suppliers. Her focus areas include project management, insight generation & reporting, and moderation of HCP and payer interviewers.

Katherine joined the healthcare industry in vaccines at Sanofi US (formerly Connaught), where her market research supported a significant US health policy shift for polio vaccines. She played pivotal roles in strategic initiatives, including a joint venture with Merck Vaccines and the development of the first sales and marketing data warehouse. At BMS, Katherine made significant contributions to marketing strategy, co-developing and executing the US market research plan for the launch of the blockbuster drug, Plavix. Her success led to several promotions, including director of strategic alliances and patient support for the oncology/immunology division, where she led a small team of directors.

Katherine holds an MBA from the University of Chicago’s Booth School of Business in marketing, finance, and operations research.  She graduated magna cum laude from Rutgers College with a BA in economics and a minor in statistics. In May 2018, she completed her MPH from Rutgers Biomedical and Health Sciences with a focus on epidemiology. Notably, she received the James Cook Research Award for her fieldwork supporting a PCORI (Patient-Centered Outcomes Research Institute) grant on psychotropic medication use in the foster care population. Additionally, she co-authored a paper titled “A best-worst case scaling experiment to identify patient-centered claims based outcomes for the evaluation of pediatric antipsychotic monitoring programs,” published in the Health Services Research Journal in 2020.